In Merck’s case, worries over rising competition from so-called ‘biosimilar’ generic products, which approximate the biological chemical structure of branded medicines, is behind much of the ...

In contrast, Goldman Sachs reaffirmed its Buy rating, highlighting Merck’s expansive oncology strategy and potential commercial opportunities exceeding $25 billion by the mid-2030s. Additionally, ...

Merck & Co., Inc. (NYSE:MRK) on Monday shared topline results from the first two of three Phase 3 clinical trials evaluating the safety and efficacy of enlicitide decanoate, an investigational ...

MoonLake shares climbed 5.5% from $39.01 to $41.16 on June 2, the day news of Merck’s interest in MoonLake surfaced, then jumped another 24% over two days to $51.05 Wednesday before fading 4% to ...

Shares of small-biotech MoonLake Immunotherapeutics MLTX rose 18% yesterday following a report issued by the Financial Times (FT), which stated that pharma giant Merck MRK is interested in ...

Shares of small-biotech MoonLake Immunotherapeutics MLTX rose 18% yesterday following a report issued by the Financial Times (FT), which stated that pharma giant Merck MRK is interested in acquiring ...

Merck submitted a non-binding offer for MoonLake earlier this year, valuing the business in excess of $3 billion, a premium to its $2.6 billion market value, but its initial approach was rejected ...